Stemline Therapeutics, Inc.
STML
STML was delisted on the 9th of June, 2020.
56 hedge funds and large institutions have $184M invested in Stemline Therapeutics, Inc. in 2013 Q2 according to their latest regulatory filings, with 56 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
TRCT
51
Tower Research Capital (TRC)
New York
| $12K | +$7.49K | +470 | New |
|
52
Barclays
London,
United Kingdom
| $11K | +$7.66K | +481 | New |
|
53
BlackRock
New York
| $6K | +$4.2K | +264 | New |
|
54
PNC Financial Services Group
Pittsburgh,
Pennsylvania
| $5K | +$3.19K | +200 | New |
|
55
Citigroup
New York
| $5K | +$3.54K | +222 | New |
|
|
SSG
56
Summit Securities Group
New York
| $1K | +$796 | +50 | New |
|
STML Hedge Fund Activity: Q2 2013 in Review
56 of the 3,064 institutional investors tracked by Wall St. Rank reported a position in Stemline Therapeutics, Inc. (STML) for Q2 2013, worth a combined $184M.
Buyers outnumbered sellers: 56 funds opened new STML positions and 0 closed out — a net gain of 56 holders — while 0 added to existing stakes and 0 trimmed.
- 56 institutional investors held Stemline Therapeutics, Inc. (STML) as of Q2 2013, up from 0 in Q1 2013.
- Funds reported $184M of Stemline Therapeutics, Inc. stock for Q2 2013.
- 56 funds opened new Stemline Therapeutics, Inc. positions in Q2 2013 and 0 closed out, a net change of +56 holders.
Based on aggregated 13F filings for Q2 2013.